AAN 2023 | Using biomarkers to tailor treatment options for MS

Augusto Miravalle, MD, FAAN, University of Colorado School of Medicine, Aurora, CO, discusses the use of biomarkers to diagnose multiple sclerosis (MS). MS manifests with a large array of symptoms, meaning that individualized therapy may be the most effective treatment approach. Serum-based biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are currently being researched, as is the application of MRI to assess the morphology and anatomical location of lesions, which may be of prognostic value. The process of segmental atrophy is also being studied as a way to understand the presence of early thalamic atrophy, with the hopes that this could act as a marker of neurodegeneration. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.